1. Generics Bulletin

Pfizer Confirms EU Pegfilgrastim Launch Plans

Follows Formal European Commission Approval For Nyvepria Biosimilar

 
• By Dave Wallace

Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.

Red_Rocket
Pfizer has confirmed a launch window for its Nyvepria pegfilgrastim biosimilar • Source: Shutterstock

Pfizer has revealed that it plans to launch its Nyvepria (pegfilgrastim) biosimilar rival to Amgen’s Neulasta in Europe early next year. The confirmation of the launch plans follows the recent formal European Commission approval of Nyvepria in the wake of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September. (Also see "Pfizer Picks Up EU Pegfilgrastim Approval" - Generics Bulletin, 24 November, 2020.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.